Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2018/12/18 03:40:04」(JST)

wiki en

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.^[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".^[2]

References

^ A.I. Graul; B. Lupone; E. Cruces; M. Stringer (2013). "2012 in Review - Part I: The Year's New Drugs and Biologics" (PDF). Drugs of Today. 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991. Archived from the original (PDF) on 2013-11-03.
^ Kato, Noriyasu; Oka, Mitsuru; Murase, Takayo; Yoshida, Masahiro; Sakairi, Masao; Yamashita, Satoko; Yasuda, Yoshika; Yoshikawa, Aya; Hayashi, Yuuji; Makino, Mitsuhiro; Takeda, Motohiro; Mirensha, Yakufu; Kakigami, Takuji (2011). "Discovery and pharmacological characterization of N-\2-({2-\(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo\1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry. 19 (23): 7221. doi:10.1016/j.bmc.2011.09.043.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

English Journal

Japanese Journal

DPP4 Inhibition Ameliorates Cardiac Function by Blocking the Cleavage of HMGB1 in Diabetic Mice After Myocardial Infarction

International Heart Journal 58(5), 778-786, 2017
NAID 130006179202

DPP-4阻害薬anagliptinはマウスにおける肝臓のインスリン抵抗性および脂肪肝炎を軽減する

金沢大学十全医学会雑誌 = Journal of the Juzen Medical Society 125(2), 79-80, 2016-06-01
NAID 120005848564

Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats

Journal of Nutritional Science and Vitaminology 61(4), 313-321, 2015
NAID 130005102612

★リンクテーブル★

リンク元

「アナグリプチン」

Anagliptin
Clinical data
Trade names	Suiny
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Approved in Japan;
Identifiers
	IUPAC name N-[2-[[2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide;
CAS Number	739366-20-2;
ChemSpider	28492667;
Chemical and physical data
Formula	C19H25N7O2
Molar mass	383.45 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N;
	InChI InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1; Key:LDXYBEHACFJIEL-HNNXBMFYSA-N;

　　[★]

英: anagliptin
商: スイニー、ベスコア
関: DPP-4阻害薬

[1] A.I. Graul; B. Lupone; E. Cruces; M. Stringer (2013). "2012 in Review - Part I: The Year's New Drugs and Biologics" (PDF). Drugs of Today. 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991. Archived from the original (PDF) on 2013-11-03.

[2] Kato, Noriyasu; Oka, Mitsuru; Murase, Takayo; Yoshida, Masahiro; Sakairi, Masao; Yamashita, Satoko; Yasuda, Yoshika; Yoshikawa, Aya; Hayashi, Yuuji; Makino, Mitsuhiro; Takeda, Motohiro; Mirensha, Yakufu; Kakigami, Takuji (2011). "Discovery and pharmacological characterization of N-\2-({2-\(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo\1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry. 19 (23): 7221. doi:10.1016/j.bmc.2011.09.043.

匿名

検索

案内

案内

anagliptin